NTLA vs PBLS: fair value comparison
Intellia Therapeutics, Inc. and Parabilis Medicines, Inc. · Updated 2026-10-19
NTLA has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. PBLS has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, NTLA currently ranks higher by quality score.
| NTLA | PBLS | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $11.42 | $22.75 |
| 12-month range | $8.04–$25.89 | $22.75–$39.47 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #191 of 301 Healthcare | #192 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | Expanding | — |
| Revenue growth | Declining | — |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Downtrend | — |
| 52-week position | The bottom quarter | The bottom quarter |
Full single-stock breakdowns: NTLA fair value analysis · PBLS fair value analysis